Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03473600 |
Recruitment Status : Unknown
Verified March 2018 by Noura Ali, Assiut University.
Recruitment status was: Not yet recruiting
First Posted : March 22, 2018
Last Update Posted : March 22, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Alopecia areata is the most frequent cause of inflammation-induced hair loss with prevalence from 0.1 to 0.2%. It has no age nor sex predilection .
Clinically, alopecia areata presents as a well-circumscribed patch of sudden hair loss. It affects any hair bearing area. The most common affected site is the scalp. Based on site and extent, AA can be classified into; diffuse, multi-locularis, mono-locularis, totalis, universalis, and ophiasis.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alopecia Areata | Procedure: Cryotherapy Drug: Triamcinolone acetonide injection | Phase 4 |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation |
Estimated Study Start Date : | November 2018 |
Estimated Primary Completion Date : | July 2019 |
Estimated Study Completion Date : | September 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: study group
•The first group (20 patients) will be treated with cryotherapy using liquid nitrogen spray, two cycles each one 3-5 seconds, one session every two weeks, for three months.
|
Procedure: Cryotherapy
Liquid Nitrogen spray |
Active Comparator: control group
•The second group (20 patients) will be treated with intralesional injection of 4mg/ml/ session of triamcinolone-acetonide, it will be injected into deep dermis or upper subcutaneous tissue using a 0.5-inch long 30-gauge needle at multiple sites, 1 cm apart and 0.1 ml into each site, once every three weeks, for three months, using insulin syringes.
|
Drug: Triamcinolone acetonide injection
Intralesional Triamcinolone Acetonide injection |
- The incidence of patietns with hair regrowth [ Time Frame: 3 months ]measuring severity of alopecia tool score and dermoscopic examination

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age >12 years.
- Both sexes will be included.
- Newly diagnosed cases.
Exclusion Criteria:
- Children < 12 years.
- Pregnancy and lactation.
- Patients with active scalp infection.
- Patients with cold sensitivity (regarding the first group).
- Any newly onset medical systemic illness.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03473600
Contact: Hanan Ahmed Morsy, Assistant professor | 01064447881 | Hanan_morsy2003@yahoo.com | |
Contact: Aya Youssef Mohamed, Lecturer | 01013244819 | Aya_badran@yahoo.com |
Egypt | |
Faculty of medicine | |
Assiut, Egypt, 71111 | |
Contact: Aya Youssef, Lecturer 01013244819 |
Responsible Party: | Noura Ali, Principal Investigator, Assiut University |
ClinicalTrials.gov Identifier: | NCT03473600 |
Other Study ID Numbers: |
CVILCsAA |
First Posted: | March 22, 2018 Key Record Dates |
Last Update Posted: | March 22, 2018 |
Last Verified: | March 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical Triamcinolone Triamcinolone Acetonide Triamcinolone hexacetonide Triamcinolone diacetate |
Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Immunosuppressive Agents Immunologic Factors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |